Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag versus IVIG before and during invasive procedures in adults with immune thrombocytopenia
NL-OMON46896Phase 3Withdrawn
- Sponsor
- HagaZiekenhuis
- Start
- Jan 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in immune thrombocytopenia (ITP) comparing Eltrombopag with Intravenous immunoglobulin (2 arms). Planned start Jan 2017; status: withdrawn.
02
Drugs
eltrombopagimmune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON46896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46896.